📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:09
535 analysed today
FollowTelegram
535
Today
149,936
All-time analysed
42,982
Positive
6,669
Negative
91,578
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Zenith Healthcare Board Approves Q1 FY27 Results; Meeting Concluded in 55 Minutes
Zenith Healthcare submitted its unaudited financial results for the quarter ended June 30, 2026, following a board meeting on August 14, 2026. The company enters this fiscal year with a TTM revenue of Rs 11 Cr and a thin net worth of Rs 7 Cr. In the preceding quarter (March 2026), the company reported a net loss of Rs 0.34 Cr on revenue of Rs 2.62 Cr. Investors need to verify the detailed P&L to see if the company has returned to profitability, as FY26 annual PAT was just Rs 0.01 Cr.
Confidence: MEDIUM
What changedThe company has formally approved and submitted its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersFor a micro-cap company with a market cap near zero and low profitability, quarterly results are critical to assess solvency and operational viability.
Meeting Duration: 55 minutesTTM Revenue: Rs 11 CrNet Worth: Rs 7 CrPromoter Holding: 28.74%Previous Quarter Net Profit (Mar 26): Rs -0.34 Cr
📅 Short termThe stock, currently priced at Rs 3.1, may see low-volume volatility as the market processes the specific profit/loss figures from the Q1 filing.
📈 Long termLimited structural significance unless the company demonstrates a consistent ability to scale revenue beyond the current Rs 10-11 Cr annual range.
⚠ Risk flags
- Micro-cap liquidity risk
- Low promoter holding (28.74%)
- History of marginal profitability/losses
Key Highlights
Board meeting commenced at 15:00 and concluded at 15:55 on August 14, 2026
Unaudited financial results for the quarter ended June 30, 2026, were approved with a Limited Review Report
Company operates with a small TTM revenue base of Rs 11 Cr and a net worth of Rs 7 Cr
Promoter holding has remained stagnant at 28.74% as of the latest March 2026 filing
👀 What to Watch
Investors should examine the full financial statement to check for revenue growth and margin recovery, specifically looking for a reversal of the Rs 0.46 Cr operating loss reported in the previous quarter.
Zenith Healthcare Approves Unaudited Financial Results for Quarter Ended June 30, 2026
Zenith Healthcare's Board of Directors met on August 14, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026. The meeting was brief, lasting 55 minutes, and included the review of the statutory auditor's report. While the specific P&L figures for the quarter were not detailed in the cover letter, the company enters this period with a TTM revenue of Rs 11 Cr and a marginal FY26 profit of Rs 0.01 Cr. This is a routine regulatory filing in compliance with SEBI LODR regulations.
Confidence: HIGH
What changedThe company has completed its internal and auditor review of the financial performance for the first quarter of the 2026-27 fiscal year.
Why it mattersAs a micro-cap pharmaceutical company with marginal profitability (Rs 0.01 Cr in FY26), quarterly results are critical to monitor for signs of operational turnaround or further margin deterioration.
TTM Revenue: Rs 11 CrNet Worth: Rs 7 CrQuarter Ended: 30th June, 2026Meeting Duration: 55 minutesTTM EPS: Rs 0.01
📅 Short termThe stock is likely to remain neutral in the short term as this is a routine earnings approval for a micro-cap entity with low trading volume.
📈 Long termLimited structural significance unless the company demonstrates a consistent ability to scale revenue beyond the current Rs 10-11 Cr annual range and improve its ROCE of 0.3%.
⚠ Risk flags
- Low promoter holding (28.7%)
- Negative operating margins (-1.4%)
- Micro-cap liquidity risk
Key Highlights
Board meeting held and concluded on August 14, 2026, between 15:00 and 15:55.
Approved unaudited financial results for the quarter ended June 30, 2026.
Company reported a TTM revenue of Rs 11 Cr prior to this announcement.
Operating profit margin (TTM) stands at -1.4%, indicating ongoing pressure on core profitability.
Promoter holding remains stable at 28.74% as of the last reporting period.
👀 What to Watch
Investors should examine the full financial statements to see if the company has improved its operating margins from the -1.4% TTM level and if revenue has grown beyond the Rs 2.62 Cr reported in the previous quarter (March 2026).
119:50 Swap Ratio: Zenith Healthcare to Merge with Larger Achyut Healthcare
Zenith Healthcare has approved a Scheme of Amalgamation to merge Achyut Healthcare Limited into itself. The swap ratio is set at 119 Zenith shares for every 50 Achyut shares, leading to a massive expansion of Zenith's equity base from 5.37 crore to 62.82 crore shares. Achyut Healthcare is significantly larger than Zenith, with a net worth of ₹35.06 crore compared to Zenith's ₹7.42 crore as of March 2026. Post-merger, promoter holding in Zenith will increase from 28.74% to 45.80%, consolidating the group's pharmaceutical operations.
Confidence: HIGH
What changedZenith Healthcare is absorbing a larger group company, Achyut Healthcare, resulting in a complete restructuring of its balance sheet and shareholding pattern.
Why it mattersThis is a transformative merger for Zenith, as it acquires an entity with 4.7x its own net worth and a new manufacturing plant under development, potentially moving the company from a small-scale player to a more integrated pharmaceutical manufacturer.
Swap Ratio: 119:50Achyut Net Worth (FY26): ₹35.06 crZenith Net Worth (FY26): ₹7.42 crPost-Merger Total Shares: 62,81,68,660Post-Merger Promoter Holding: 45.80%
📅 Short termThe stock may see volatility as the market digests the massive equity dilution versus the substantial asset addition.
📈 Long termIf the new manufacturing facility is commissioned successfully and synergies are realized, the merged entity will have a much stronger financial profile and broader product portfolio.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Massive equity dilution (share count increasing >10x)
- Related party transaction (same promoter group)
- Execution risk of the new manufacturing facility under development
Key Highlights
Swap ratio of 119 equity shares of Zenith (FV ₹1) for every 50 equity shares of Achyut (FV ₹1)
Zenith's total equity share count to increase by approximately 1,069% from 5.37 crore to 62.82 crore shares
Achyut Healthcare brings ₹38.09 crore in assets and ₹11.97 crore in turnover (FY26) to the combined entity
Promoter stake in Zenith will rise significantly from 28.74% to 45.80% post-amalgamation
Achyut is currently developing a new manufacturing facility for tablets, capsules, and liquid inhalation in Ahmedabad
👀 What to Watch
Investors should monitor the NCLT approval timeline and the progress of Achyut's new manufacturing facility, which is intended to provide EU-GMP standards. The massive equity dilution is offset by the absorption of a much larger asset base and higher net worth entity.
119:50 Swap Ratio: Zenith Healthcare to Merge with Achyut Healthcare in Major Expansion
Zenith Healthcare has approved a scheme of amalgamation to merge Achyut Healthcare Limited into itself. The merger is significant as Achyut Healthcare (FY26 Net Worth: ₹35.06 cr) has a balance sheet nearly 4.7x larger than Zenith's (FY26 Net Worth: ₹7.42 cr). Shareholders of Achyut will receive 119 shares of Zenith for every 50 shares held. This transaction will result in a massive equity expansion, with Zenith's total shares increasing from 5.37 cr to 62.82 cr, while promoter holding will rise from 28.74% to 45.80%.
Confidence: HIGH
What changedZenith Healthcare is absorbing Achyut Healthcare, a related-party entity with a larger asset base and upcoming manufacturing capacities.
Why it mattersThe merger fundamentally changes Zenith's scale, moving it from a small-cap entity with ₹10.9 cr turnover to a combined entity with nearly double the revenue and a 4.7x larger net worth, while consolidating promoter control.
Swap Ratio: 119:50Achyut Net Worth (FY26): ₹35.06 crZenith Net Worth (FY26): ₹7.42 crPost-Merger Total Shares: 62,81,68,660Post-Merger Promoter Holding: 45.80%
📅 Short termThe stock may see volatility as the market digests the massive 11.7x equity dilution against the backdrop of a significantly improved asset base.
📈 Long termIf the new manufacturing facilities are commissioned successfully, the combined entity could achieve much higher economies of scale and a broader product portfolio in the API and formulation segments.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Massive equity dilution
- Related-party transaction
- Execution risk of new manufacturing plant
- Regulatory approval risk (NCLT/BSE)
Key Highlights
Swap ratio fixed at 119 equity shares of Zenith (FV ₹1) for every 50 equity shares of Achyut (FV ₹1).
Achyut Healthcare brings a significantly stronger balance sheet with total assets of ₹38.09 cr vs Zenith's ₹10.99 cr as of March 2026.
Total equity base of Zenith to expand by approximately 1,069% from 5.37 cr shares to 62.82 cr shares.
Promoter stake in the combined entity will increase to 45.80% from the current 28.74%.
Achyut is currently establishing new manufacturing facilities for General Tablets, Capsules, and Liquid Inhalation products in Gujarat.
👀 What to Watch
Investors should monitor the timeline for NCLT and shareholder approvals, and specifically track the commissioning of Achyut's new manufacturing facility which is a core driver of this merger.
Zenith Healthcare to Merge with Achyut Healthcare; Swap Ratio 119:50; Share Capital to Jump 11x
Zenith Healthcare has approved the merger of Achyut Healthcare Limited into itself. Achyut is significantly larger, with a net worth of Rs 35.06 cr compared to Zenith's Rs 7.42 cr as of March 2026. The deal involves a swap ratio of 119 Zenith shares for every 50 Achyut shares, which will expand Zenith's total share count from 5.37 crore to 62.82 crore. Post-merger, the promoter stake in Zenith will increase from 28.74% to 45.80%, while the company gains Achyut's upcoming manufacturing facility in Ahmedabad.
Confidence: HIGH
What changedZenith Healthcare is absorbing a larger related-party entity, Achyut Healthcare, leading to a massive expansion of its balance sheet and share capital.
Why it mattersThis merger fundamentally changes Zenith's scale, adding significant assets and a new manufacturing plant, though it comes at the cost of massive equity dilution for existing shareholders.
Swap Ratio: 119:50Achyut Net Worth (Mar-26): Rs 35.06 crZenith Net Worth (Mar-26): Rs 7.42 crPost-Merger Share Count: 62,81,68,660Promoter Stake Change: 28.74% to 45.80%
📅 Short termThe market is likely to react to the significant asset addition, though the massive dilution of the share base may temper immediate price gains.
📈 Long termIf the new manufacturing facility is successfully commissioned, the combined entity could achieve much higher revenue scales than Zenith's current standalone operations.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Massive equity dilution (share count increases ~11.7x)
- Related-party transaction (same promoter group)
- Subject to NCLT and regulatory approvals
Key Highlights
Swap ratio fixed at 119 equity shares of Zenith (FV Rs 1) for every 50 shares of Achyut Healthcare.
Achyut Healthcare brings a net worth of Rs 35.06 cr, which is 4.7x Zenith's current net worth of Rs 7.42 cr.
Total equity shares of Zenith will increase by approximately 11.7x, from 5.37 crore to 62.82 crore shares.
Promoter holding in the combined entity will rise to 45.80% from the current 28.74%.
Achyut is currently commissioning a new manufacturing facility for tablets, capsules, and liquid inhalation products.
👀 What to Watch
Investors should monitor the NCLT approval timeline and the progress of Achyut's new manufacturing facility, as the merger's value depends on the successful integration of these new production lines.
